Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TR-701 FA with Tyramine · 1 trial · 1 indication
To assess tyramine dose required to cause increase of 30 mmHg in systolic blood pressure
| Arm | Type | Description |
|---|---|---|
| TR-701 FA with Tyramine | EXPERIMENTAL | TR-701 FA 200 oral with Tyramine |
| Placebo-controlled with Tyramine | PLACEBO_COMPARATOR | Placebo-controlled with Tyramine |
| Name | Type | Description |
|---|---|---|
| TR-701 FA with Tyramine | DRUG | TR-701 FA 200 mg oral and Tyramine |
| Placebo-controlled withTyramine | DRUG | Placebo-controlled and Tyramine |
Inclusion Criteria: * Male or female subjects between 18 to 45 years of age, inclusive * Body mass index between 19 kg/m2 and 31 kg/m2, inclusive * Healthy subjects with no clinically significant abnormalities identified by a detailed medical history, Exclusion Criteria: * Systolic blood pressure...
TR-701 FA is an investigational small molecule being studied for bacterial infections, including skin and subcutaneous tissue bacterial infections such as major cutaneous abscess, cellulitis, and erysipelas. It has also been evaluated in healthy volunteers and in subjects with hepatic impairment.
TR-701 FA is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company has sponsored clinical trials of the drug in the United States.
TR-701 FA is in Phase 1 clinical development. It has completed Phase 1 trials, and one Phase 2 trial has also been completed. The drug remains investigational and is not yet approved for any use.
TR-701 FA has completed several clinical trials, including NCT00983255, a Phase 1 ascending dose pharmacokinetic and absolute bioavailability study in bacterial infections; NCT01461460, a thorough QT study in healthy subjects; NCT01496677, a pharmacokinetics, safety, and tolerability study in elderly subjects; and NCT01519778, a Phase 2 safety and exploratory skin lesion measurement study.
Yes, TR-701 FA stands for TR-701 free acid. Clinical trial titles refer to TR-701 free acid (FA), and the drug is identified by the same name across studies. It is an investigational small molecule being studied for bacterial infections.